Day 1: Wednesday 25 November 2015

9:00am-3:00pm MRTA Workshop (by invitation only)
5:00pm-5:30pm Registration

Welcome Reception 

Translational Research Institute Atrium

Day 2: Thursday 26 November 2015

8:00am-9:00am Registration
9:00am-9:15am Welcome and Introduction to the TRI
Colleen Nelson & Carolyn Mountford
9:15am-10:00am Session 1 – Development of new targeted therapies (including adaptive) Chair: Jeff Holst
Therapeutic targeting of ETS factor ERG for the treatment of prostate cancer Miriam Butler
Intravital discovery of microRNA-drivers of metastasis in human cancer Lian Willetts
Targeting amino acid transporters in prostate cancer Kevin Wang
Targeting Neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance Marianna Volpert
Dual inhibition of RNA Pol I transcription and PIM kinase as a new therapy to treat prostate cancer Luc Furic
10:00am-10:45am Session 2 – Targeting metabolic pathways Chair: Lisa Butler
Targeting glutamine and leucine addiction in prostate cancer Jeff Holst
Targeting metabolic drivers of prostate cancer resistance and survival Jennifer Gunter
Inhibition of de novo fatty acid synthesis suppresses androgen signalling in prostate cancer Martin Sadowski
Targeting fatty acid metabolism in prostate cancer Matthew Watt

Leptin: Classical Adipokine Peptide Hormone Controlling Systemic Energy Balance – a Role in Advanced Prostate Cancer?

Lisa Philp
10:45am-11:15am Morning Tea
11:15am-12:00pm Session 3 – Drugging the undruggable and MOA of novel drugs Chair: Amina Zoubeidi
Targeting FoxM1 in Enzalutamide resistant prostate cancer Amina Zoubeidi
Investigation in prostate cancer cells of a new mitotic inhibitor isolated from an Australian endemic rainforest tree Claire Levrier

Targeting the long non-coding RNA GHSROS, a mediator of prostate cancer tumour growth, with short antisense oligonucleotides

Lisa Chopin
The role of microRNA-194 in prostate cancer metastasis Rajdeep Das
Multimodal hyperbranched polymers for prostate cancer theranostics Brian Tse
12:00pm-1:00pm Session 4 - Development of Diagnostic, Prognostic and Predictive Biomarkers for Patient Stratification
Chair: William Watson
Risk calculators for patient stratification in early stage disease William Watson
Glypican-1: a new biomarker for detection of prostate cancer Mei Yeh
Interrogating the prostate cancer lipidome Maggie Centenera
Analysis of cytokine expression in prostate cancer patients undergoing radiation therapy: correlation with clinicopathological outcomes Jagtar Singh
Assessment of extracellular vesicles for prognostic biomarkers in advanced prostate cancer Carolina Soekmadji
Taxane resistance biomarkers in advanced prostate cancer Kate Mahon
1:00pm-1:45pm Lunch
1:45pm-2:30pm Bus transport to Lone Pine Koala Sanctuary
2:30pm-3:00pm Guided tour at Lone Pine Koala Sanctuary
3:00pm-4:45pm Free time at Lone Pine Koala Sanctuary
4:45pm-6:45pm Brisbane River Boat Cruise from Lone Pine Koala Sanctuary to Southbank

Day 3: Friday 27 November 2015


APCRCs Research Coordination Committee Meeting

(by invitation only)

9:00am-9:15am Delegate Arrival and Settling In
9:15am-10:00am Session 5 – Using transcriptomics and big data in tumour response Chair: Luke Selth
Team Transcriptomics Melanie Lehman
(via videolink)
Analysis and storage of transcriptomic data in the cloud Nenad Bartonicek
Weighted gene co-expression in network analysis using RNA-Seq data Chenwei Wang
Tracking subclonal dynamics in lethal prostate cancer Chris Hovens
10:00am-10:45am Session 6 – Taking genomic discovery into the clinic Chair: Bharati Bapat
Validation of urinary methylation biomarkers for non-invasive prognostication of prostate cancer patients: A Movember GAP Project Bharati Bapat
Creating and validating biomarkers for intermediate-risk disease from whole genome sequencing Paul Boutros
Predicting metastatic potential at diagnosis from tumours and blood Niall Corcoran
Mining the microenvironment methylome to identify novel prostate cancer biomarkers Ruth Pidsley
SNP bases to basis of prostate cancer in post GWAS era Jyotsna Batra

Predicting prostate cancer-specific mortality at diagnosis: can next-gen  technologies get us there?

Liesel FitzGerald
10:45am-11:15am Morning Tea
11:15am-12:15pm Session 7 – Tumour biology Chair: David Waugh
Early Genetics Events in Prostate Carcinogenesis Ed Gelmann
Genetic basis and therapeutic consequences of inflammatory Interleukin-8 signalling David Waugh
GRHL2 regulates androgen receptor signalling and maintains epithelial identity in prostate cancer Luke Selth
Identification of a novel RLN1-RLN2 fusion transcript in prostate cancer Gregor Tevz
Intraductal carcinoma in high risk prostate cancer Mitch Lawrence
12:15pm-2:00pm Lunch & TRI tours
2:00pm-2:45pm Session 8 – Tumour Cell Plasticity- Cancer’s Master of Disguise Chair: Elizabeth Williams
A spontaneous developmental lineage plasticity that underlies the response of prostate cancer cells to androgen deprivation Amy Lubik
The role of ZEB1 in ATT-induced cellular plasticity Katrina Sweeney

RB1 loss drives trans-differentiation to neuroendocrine prostate cancer

Leigh Ellis
Revealing the transcriptional landscape of epithelial-mesenchymal plasticity in prostate cancer progression Brett Hollier
2:45pm-3:30pm Session 9 – Modelling and Targeting the Tumour-Bone Microenvironment Chair: Renea Taylor
PDX models for identifying early drivers in prostate cancer progression YZ Wang
3D melt-electrospun scaffold-based models to study localised prostate cancer Natalie Lister
A tissue engineering approach to develop humanised mice models of bone metastasis Laure Martine
Modelling prostate cancer-induced formation in vitro Elizabeth Williams
Proteases as Key Drivers of Prostate Cancer Progression Judith Clements
3:30pm-5:30pm Poster Reception
7:00pm-10:30pm Symposium Dinner
Room Three Sixty, QUT Gardens Point Campus

Day 4: Saturday 28 November 2015

9:15am-9:30am Delegate Arrival and Settling In

Session 10 - Prostate Cancer Research Forum: Contemporary issues and advances in prostate cancer management

(open to public)

This session will feature presentations from a multidisciplinary team with audience participation encouraged through a Q&A panel discussion

Moderator: Colleen Nelson
Integrating multidisciplinary team management Ian Vela
Diverse landscape of radiation oncology: from targeted to systemic Rob Bristow
(Radiation Oncologist)
Bringing trials to patients and patients to trials Carmel Pezaro (Medical Oncologist)
Sarcopenia: Its effects and treatment options Justin Keogh
(Exercise Physiologist)
Exercise and Nutrition in prostate cancer management Tina Skinner
(Exercise Physiologist and Nutritionist)
Nutrition and nutraceuticals

Cheri Van Patten
(Oncology Dietician)

Prostate cancer nursing and palliative care Patsy Yates
(Prostate Cancer Nursing & Palliative Care)
TrueNth:  Navigating access to best practice care Cyril Dixon
(TrueNTH Coordinated Care Models)
Q&A 40 minute Discussion Panel
11:00am-11:30am Morning Tea

Session 11 - Prostate Cancer Research Forum: Leading translational advances in prostate cancer

(open to public)

Chair: Carmel Pezaro and Ian Vela
Targetable and actionable mutations in localized prostate: fact or function? Rob Bristow
Challenges in Advanced Prostate Cancer: Learning to Use the Drugs We Have Carmel Pezaro
CTC and organoid in vitro culture technology in advanced prostate cancer precision medicine Ian Vela
Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer Arun Azad
Implications of molecular imaging on modern day prostate cancer management: Diagnosis, Treatment, and Follow Up Handoo Rhee
New approaches to combined imaging and therapy for prostate cancer Pamela Russell

Session 12 – Prostate Cancer Research Forum: Update on new collaborative opportunities and initiatives

(open to public)

Chair: Colleen Nelson

Movember's recent and upcoming initiatives

Paul Villanti
Closing remarks Colleen Nelson
1:30pm-2:30pm Lunch
© COPYRIGHT 2015 The Prostate Cancer Collaborative Research Alliance    |    SITE BY MOOBALL IT
Mooball IT